Small molecules as agonists or antagonists [93, 94], which are able to modulate specifically the APOBEC3G and APOBEC3B levels and activities, respectively, can be as well considered as starting points for further development of combinatorial drug applications in ovarian cancer. The gene discussed is APOBEC3B; the disease is ovarian carcinoma.